A Phase 2 interventional study of INCB054707 and Placebo in Hidradenitis Suppurativa and Acne Inversa, sponsored by Incyte Corporation. Completed at 40 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 5 in phase 2, and was the 3rd registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Canada
Ages 12–17
Incyte Corporation · Sites in United States
Ages 12–75
Incyte Corporation · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 209 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 391 across the 12 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
2 of the studies in Hidradenitis Suppurativa by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT07049575Incyte CorporationStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | 2026-12-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive INCB054707 15 milligrams (mg) for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
Drug: INCB054707
Participants will receive INCB054707 45 mg for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
Drug: INCB054707
Participants will receive INCB054707 75 mg for 52 weeks in the Placebo-controlled Treatment Period (16 weeks) plus the Open-label Extension Period (36 weeks). Participants will have the option to continue open-label treatment for an additional 48 weeks.
Drug: INCB054707
Participants will receive placebo for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
Drug: Placebo
Oral; Tablet
Also known as: Povorcitinib
Oral; Tablet
Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The mixed model repeated measure (MMRM) included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.
Time frame: Baseline; Week 16
Percentage of Participants Who Achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
HiSCR, the key secondary endpoint, was defined as at least a 50% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.
Time frame: Baseline; Week 16
Percentage of Participants Who Achieved a HiSCR at Weeks 2 Through 12
HiSCR was defined as at least a 50% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.
Time frame: Baseline; Weeks 2, 4, 6, 8, and 12
Percentage of Participants Who Achieved HiSCR75 From Weeks 2 to 16
HiSCR75 was defined as at least a 75% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.
Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16
Mean Change From Baseline in the Severity of the Disease, as Assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4) Score, From Weeks 2 to 16
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The IHS4 is a composite, dynamic score and validated tool used to determine Hidradenitis Suppurativa severity. It employs a weighted scale using the number of inflammatory nodules, the number of abscesses, and the number of draining tunnels (fistulas or sinuses), with respective weight factors of 1, 2, and 4. Scores: mild=0-3; moderate=4-10; severe ≥11. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.
Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16
Percentage of Participants Who Achieved AN50, AN75, AN90, and AN100 From Weeks 2 to 16
AN50, AN75, AN90, and AN100 were defined as at least a 50%, 75%, 90%, and 100% decrease, respectively, from Baseline in AN count.
Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16
Mean Change From Baseline in AN Count at Weeks 2 to 12
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.
Time frame: Baseline; Weeks 2, 4, 6, 8, and 12
Percentage of Participants With a Total AN Count of 0 to 2 From Weeks 2 to 16
Total AN count was assessed throughout the study.
Time frame: Weeks 2, 4, 6, 8, 12, and 16
Mean Change From Baseline in Draining Fistula Count From Weeks 2 to 16
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16
Mean Change From Baseline in Abscess, Inflammatory Nodule (IN), and Draining Fistula (DF) (ANF) Count From Weeks 2 to 16
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.
Time frame: Baseline; Weeks 2, 4, 6, 8, 12, and 16
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.
Time frame: up to Week 16
A total of 209 participants were enrolled at 36 study centers: 26 in North America and 10 in Europe. Data are reported through the cut-off date of 15 December 2021.
| Milestone | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Started | 52 | 52 | 52 | 53 |
| Completed | 48 | 47 | 45 | 51 |
| Not completed | 4 | 5 | 7 | 2 |
| Withdrew: Withdrawal by subject | 1 | 3 | 4 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 1 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The mixed model repeated measure (MMRM) included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.
| abscesses and inflammatory nodules | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 | -2.5 ± 0.88 | -5.2 ± 0.86 | -6.9 ± 0.88 | -6.3 ± 0.85 |
HiSCR, the key secondary endpoint, was defined as at least a 50% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.
| percentage of participants | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Percentage of Participants Who Achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | 28.8 (17.1 to 43.1) | 48.1 (34.0 to 62.4) | 44.2 (30.5 to 58.7) | 45.3 (31.6 to 59.6) |
HiSCR was defined as at least a 50% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.
| percentage of participants | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Week 2 | 15.4 (6.9 to 28.1) | 25.0 (14.0 to 38.9) | 34.6 (22.0 to 49.1) | 34.0 (21.5 to 48.3) |
| Week 4 | 25.0 (14.0 to 38.9) | 36.5 (23.6 to 51.0) | 44.2 (30.5 to 58.7) | 49.1 (35.1 to 63.2) |
| Week 6 | 17.3 (8.2 to 30.3) | 32.7 (20.3 to 47.1) | 48.1 (34.0 to 62.4) | 52.8 (38.6 to 66.7) |
| Week 8 | 28.8 (17.1 to 43.1) | 36.5 (23.6 to 51.0) | 44.2 (30.5 to 58.7) | 52.8 (38.6 to 66.7) |
| Week 12 | 30.8 (18.7 to 45.1) | 42.3 (28.7 to 56.8) | 48.1 (34.0 to 62.4) | 58.5 (44.1 to 71.9) |
HiSCR75 was defined as at least a 75% decrease from Baseline in AN count with no increase in the number of abscesses or draining fistulas.
| percentage of participants | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Week 2 | 1.9 (0.0 to 10.3) | 9.6 (3.2 to 21.0) | 13.5 (5.6 to 25.8) | 18.9 (9.4 to 32.0) |
| Week 4 | 7.7 (2.1 to 18.5) | 15.4 (6.9 to 28.1) | 21.2 (11.1 to 34.7) | 15.1 (6.7 to 27.6) |
| Week 6 | 9.6 (3.2 to 21.0) | 17.3 (8.2 to 30.3) | 28.8 (17.1 to 43.1) | 24.5 (13.8 to 38.3) |
| Week 8 | 19.2 (9.6 to 32.5) | 23.1 (12.5 to 36.8) | 30.8 (18.7 to 45.1) | 35.8 (23.1 to 50.2) |
| Week 12 | 19.2 (9.6 to 32.5) | 26.9 (15.6 to 41.0) | 32.7 (20.3 to 47.1) | 39.6 (26.5 to 54.0) |
| Week 16 | 17.3 (8.2 to 30.3) | 30.8 (18.7 to 45.1) | 28.8 (17.1 to 43.1) | 30.2 (18.3 to 44.3) |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The IHS4 is a composite, dynamic score and validated tool used to determine Hidradenitis Suppurativa severity. It employs a weighted scale using the number of inflammatory nodules, the number of abscesses, and the number of draining tunnels (fistulas or sinuses), with respective weight factors of 1, 2, and 4. Scores: mild=0-3; moderate=4-10; severe ≥11. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.
| scores on a scale | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Week 2 | -2.4 ± 1.17 | -3.8 ± 1.13 | -6.7 ± 1.16 | -6.1 ± 1.12 |
| Week 4 | -2.1 ± 1.52 | -3.9 ± 1.49 | -9.3 ± 1.51 | -9.3 ± 1.47 |
| Week 6 | -3.1 ± 1.77 | -4.7 ± 1.73 | -10.7 ± 1.75 | -10.6 ± 1.71 |
| Week 8 | -3.0 ± 1.85 | -4.0 ± 1.79 | -11.8 ± 1.83 | -10.7 ± 1.78 |
| Week 12 | -3.1 ± 1.80 | -5.5 ± 1.76 | -11.8 ± 1.79 | -11.9 ± 1.73 |
| Week 16 | -3.1 ± 1.96 | -5.6 ± 1.92 | -11.0 ± 1.96 | -12.1 ± 1.90 |
AN50, AN75, AN90, and AN100 were defined as at least a 50%, 75%, 90%, and 100% decrease, respectively, from Baseline in AN count.
| percentage of participants | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| AN50, Week 2 | 15.4 (6.9 to 28.1) | 25.0 (14.0 to 38.9) | 34.6 (22.0 to 49.1) | 39.6 (26.5 to 54.0) |
| AN50, Week 4 | 30.8 (18.7 to 45.1) | 44.2 (30.5 to 58.7) | 46.2 (32.2 to 60.5) | 58.5 (44.1 to 71.9) |
| AN50, Week 6 | 32.7 (20.3 to 47.1) | 46.2 (32.2 to 60.5) | 51.9 (37.6 to 66.0) | 56.6 (42.3 to 70.2) |
| AN50, Week 8 | 36.5 (23.6 to 51.0) | 55.8 (41.3 to 69.5) | 53.8 (39.5 to 67.8) | 54.7 (40.4 to 68.4) |
| AN50, Week 12 | 44.2 (30.5 to 58.7) | 51.9 (37.6 to 66.0) | 55.8 (41.3 to 69.5) | 62.3 (47.9 to 75.2) |
| AN50, Week 16 | 36.5 (23.6 to 51.0) | 55.8 (41.3 to 69.5) | 57.7 (43.2 to 71.3) | 52.8 (38.6 to 66.7) |
| AN75, Week 2 | 1.9 (0.0 to 10.3) | 9.6 (3.2 to 21.0) | 13.5 (5.6 to 25.8) | 20.8 (10.8 to 34.1) |
| AN75, Week 4 | 7.7 (2.1 to 18.5) | 15.4 (6.9 to 28.1) | 23.1 (12.5 to 36.8) | 18.9 (9.4 to 32.0) |
| AN75, Week 6 | 13.5 (5.6 to 25.8) | 25.0 (14.0 to 38.9) | 32.7 (20.3 to 47.1) | 26.4 (15.3 to 40.3) |
| AN75, Week 8 | 21.2 (11.1 to 34.7) | 28.8 (17.1 to 43.1) | 32.7 (20.3 to 47.1) | 37.7 (24.8 to 52.1) |
| AN75, Week 12 | 23.1 (12.5 to 36.8) | 32.7 (20.3 to 47.1) | 36.5 (23.6 to 51.0) | 39.6 (26.5 to 54.0) |
| AN75, Week 16 | 17.3 (8.2 to 30.3) | 36.5 (23.6 to 51.0) | 36.5 (23.6 to 51.0) | 34.0 (21.5 to 48.3) |
| AN90, Week 2 | 0.0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 1.9 (0.0 to 10.3) | 11.3 (4.3 to 23.0) |
| AN90, Week 4 | 0.0 (0.0 to 6.8) | 5.8 (1.2 to 15.9) | 7.7 (2.1 to 18.5) | 5.7 (1.2 to 15.7) |
| AN90, Week 6 | 5.8 (1.2 to 15.9) | 5.8 (1.2 to 15.9) | 11.5 (4.4 to 23.4) | 9.4 (3.1 to 20.7) |
| AN90, Week 8 | 5.8 (1.2 to 15.9) | 15.4 (6.9 to 28.1) | 19.2 (9.6 to 32.5) | 18.9 (9.4 to 32.0) |
| AN90, Week 12 | 5.8 (1.2 to 15.9) | 17.3 (8.2 to 30.3) | 13.5 (5.6 to 25.8) | 20.8 (10.8 to 34.1) |
| AN90, Week 16 | 3.8 (0.5 to 13.2) | 17.3 (8.2 to 30.3) | 19.2 (9.6 to 32.5) | 18.9 (9.4 to 32.0) |
| AN100, Week 2 | 0.0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 1.9 (0.0 to 10.3) | 7.5 (2.1 to 18.2) |
| AN100, Week 4 | 0.0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 5.8 (1.2 to 15.9) | 5.7 (1.2 to 15.7) |
| AN100, Week 6 | 0.0 (0.0 to 6.8) | 3.8 (0.5 to 13.2) | 7.7 (2.1 to 18.5) | 9.4 (3.1 to 20.7) |
| AN100, Week 8 | 3.8 (0.5 to 13.2) | 13.5 (5.6 to 25.8) | 11.5 (4.4 to 23.4) | 17.0 (8.1 to 29.8) |
| AN100, Week 12 | 3.8 (0.5 to 13.2) | 13.5 (5.6 to 25.8) | 11.5 (4.4 to 23.4) | 18.9 (9.4 to 32.0) |
| AN100, Week 16 | 3.8 (0.5 to 13.2) | 15.4 (6.9 to 28.1) | 11.5 (4.4 to 23.4) | 17.0 (8.1 to 29.8) |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.
| abscesses and inflammatory nodules | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Week 2 | -1.7 ± 0.69 | -2.7 ± 0.66 | -3.4 ± 0.69 | -4.0 ± 0.66 |
| Week 4 | -3.0 ± 0.71 | -3.6 ± 0.70 | -4.8 ± 0.71 | -5.3 ± 0.69 |
| Week 6 | -2.7 ± 0.77 | -4.8 ± 0.76 | -5.3 ± 0.77 | -6.2 ± 0.75 |
| Week 8 | -2.7 ± 0.82 | -4.7 ± 0.79 | -6.4 ± 0.82 | -5.7 ± 0.79 |
| Week 12 | -2.8 ± 0.84 | -5.0 ± 0.82 | -6.7 ± 0.84 | -6.5 ± 0.81 |
Total AN count was assessed throughout the study.
| percentage of participants | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Week 2 | 4.3 | 9.8 | 16.7 | 23.1 |
| Week 4 | 14.3 | 20.0 | 20.0 | 23.1 |
| Week 6 | 13.3 | 19.1 | 31.3 | 38.8 |
| Week 8 | 28.9 | 30.0 | 38.3 | 41.2 |
| Week 12 | 28.9 | 33.3 | 46.7 | 38.8 |
| Week 16 | 25.6 | 44.4 | 51.2 | 37.0 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| draining fistulas | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Baseline | 2.4 ± 3.97 | 2.3 ± 4.44 | 2.2 ± 4.04 | 1.6 ± 2.85 |
| Change from Baseline at Week 2 | -0.2 ± 1.23 | -0.2 ± 1.01 | -0.6 ± 1.62 | -0.2 ± 1.30 |
| Change from Baseline at Week 4 | 0.0 ± 1.80 | 0.0 ± 1.11 | -0.8 ± 2.59 | -0.6 ± 2.44 |
| Change from Baseline at Week 6 | -0.2 ± 2.14 | 0.1 ± 1.85 | -1.0 ± 2.95 | -0.8 ± 2.62 |
| Change from Baseline at Week 8 | -0.2 ± 2.46 | 0.2 ± 2.10 | -1.1 ± 2.82 | -0.8 ± 2.70 |
| Change from Baseline at Week 12 | -0.3 ± 2.17 | 0.0 ± 2.71 | -1.0 ± 2.87 | -1.0 ± 2.61 |
| Change from Baseline at Week 16 | -0.3 ± 2.05 | 0.1 ± 3.25 | -0.8 ± 3.20 | -1.1 ± 2.57 |
Change from Baseline was calculated as the post-Baseline value minus the Baseline value. MMRM included the fixed effects of treatment group (placebo and INCB054707 15, 45, and 75 mg), stratification factors (disease severity \[Hurley Stage I, II, and III\] and geographical region \[North America and outside of North America\]), visit (Weeks 2, 4, 6, 8, 12, and 16), treatment by visit interaction, and covariates of Baseline measurement and Baseline measurement by visit interaction. The variance-covariance matrix of the within-participant errors in MMRM are modeled as unstructured.
| abscesses, INs, and DFs | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Week 2 | -1.8 ± 0.74 | -2.9 ± 0.72 | -4.0 ± 0.74 | -4.4 ± 0.71 |
| Week 4 | -2.7 ± 0.83 | -3.5 ± 0.82 | -5.7 ± 0.82 | -6.2 ± 0.80 |
| Week 6 | -2.6 ± 0.92 | -4.7 ± 0.90 | -6.4 ± 0.92 | -7.1 ± 0.89 |
| Week 8 | -2.6 ± 0.96 | -4.4 ± 0.93 | -7.5 ± 0.96 | -6.8 ± 0.92 |
| Week 12 | -2.7 ± 0.99 | -5.0 ± 0.97 | -7.7 ± 0.98 | -7.6 ± 0.95 |
| Week 16 | -2.4 ± 1.06 | -5.1 ± 1.03 | -7.7 ± 1.05 | -7.6 ± 1.02 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.
| Participants | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 34 | 31 | 30 | 32 |
Collected over up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/52 (0%) | 3/52 (5.8%) | 15/52 (28.8%) |
| INCB054707 15 mg | 0/52 (0%) | 2/52 (3.8%) | 20/52 (38.5%) |
| INCB054707 45 mg | 0/50 (0%) | 1/50 (2%) | 17/50 (34%) |
| INCB054707 75 mg | 0/53 (0%) | 0/53 (0%) | 19/53 (35.8%) |
| Event | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/52 | 0/52 | 1/50 | 0/53 |
| Abscess limbInfections and infestations | 1/52 | 0/52 | 0/50 | 0/53 |
| Atrial fibrillationCardiac disorders | 1/52 | 0/52 | 0/50 | 0/53 |
| Bacterial infectionInfections and infestations | 1/52 | 0/52 | 0/50 | 0/53 |
| CholecystitisHepatobiliary disorders | 1/52 | 0/52 | 0/50 | 0/53 |
| FallInjury, poisoning and procedural complications | 0/52 | 1/52 | 0/50 | 0/53 |
| PneumoniaInfections and infestations | 0/52 | 1/52 | 0/50 | 0/53 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/52 | 1/52 | 0/50 | 0/53 |
| Rib fractureInjury, poisoning and procedural complications | 0/52 | 1/52 | 0/50 | 0/53 |
| Event | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg |
|---|---|---|---|---|
| FatigueGeneral disorders | 4/52 | 5/52 | 6/50 | 6/53 |
| HeadacheNervous system disorders | 5/52 | 4/52 | 3/50 | 4/53 |
| NauseaGastrointestinal disorders | 5/52 | 3/52 | 2/50 | 3/53 |
| ConstipationGastrointestinal disorders | 2/52 | 4/52 | 0/50 | 1/53 |
| Upper respiratory tract infectionInfections and infestations | 2/52 | 0/52 | 1/50 | 4/53 |
| AcneSkin and subcutaneous tissue disorders | 0/52 | 1/52 | 3/50 | 3/53 |
| NasopharyngitisInfections and infestations | 0/52 | 3/52 | 3/50 | 0/53 |
| Back painMusculoskeletal and connective tissue disorders | 1/52 | 3/52 | 1/50 | 0/53 |
| DiarrhoeaGastrointestinal disorders | 1/52 | 3/52 | 2/50 | 3/53 |
| VomitingGastrointestinal disorders | 0/52 | 3/52 | 2/50 | 1/53 |
| Age, Continuous(years) | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg | Total |
|---|---|---|---|---|---|
| Mean | 35.2 ± 9.96 | 38.2 ± 10.85 | 37.3 ± 12.51 | 37.5 ± 10.83 | 37.1 ± 11.05 |
| Sex: Female, Male(Participants) | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg | Total |
|---|---|---|---|---|---|
| Female | 43 | 37 | 39 | 39 | 158 |
| Male | 9 | 15 | 13 | 14 | 51 |
| Race/Ethnicity, Customized(Participants) | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg | Total |
|---|---|---|---|---|---|
| White/Caucasian | 40 | 36 | 35 | 36 | 147 |
| Black/African American | 10 | 13 | 12 | 16 | 51 |
| Asian | 1 | 2 | 2 | 1 | 6 |
| American Indian/Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Captured as Other | 1 | 1 | 2 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 5 | 7 | 6 | 28 |
| Not Hispanic or Latino | 41 | 47 | 44 | 47 | 179 |
| Unknown | 1 | 0 | 0 | 0 | 1 |
| Captured as Other | 0 | 0 | 1 | 0 | 1 |
| Mean abscess and inflammatory nodule (AN) count(abscesses and inflammatory nodules) | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg | Total |
|---|---|---|---|---|---|
| Mean | 11.2 ± 5.85 | 11.8 ± 7.10 | 12.9 ± 12.34 | 10.6 ± 7.24 | 11.6 ± 8.48 |
| Mean International Hidradenitis Suppurativa Severity Score System (IHS4) score(scores on a scale) | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg | Total |
|---|---|---|---|---|---|
| Mean | 22.9 ± 17.02 | 22.4 ± 23.24 | 23.5 ± 22.79 | 18.9 ± 17.25 | 21.9 ± 20.21 |
| Mean abscess, inflammatory nodule (IN), and draining fistula (DF) (ANF) count(abscesses, INs, and DFs) | Placebo | INCB054707 15 mg | INCB054707 45 mg | INCB054707 75 mg | Total |
|---|---|---|---|---|---|
| Mean | 13.6 ± 6.36 | 14.1 ± 10.08 | 15.1 ± 13.51 | 12.2 ± 8.94 | 13.7 ± 10.03 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Aug 2020 to primary completion in Dec 2021, 15 months.
Results were first posted in Jan 2023, 1 year 1 month after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 15 months is close to that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Povorcitinib